Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 2 art units • 2 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Kalivir Immunotherapeutics Inc. maintains a patent portfolio focused on the Biotechnology & Pharmaceuticals technology area. There are currently 5 pending office actions across the portfolio. These actions are being reviewed by 2 distinct examiners, suggesting a concentrated but not entirely singular review process.
The portfolio's activity spans 2 distinct art units. ARON, KIMBERLY A is the busiest examiner for the company, currently managing 4 busiest examiner pending actions. This indicates that the vast majority of the company's 5 pending office actions are concentrated under one individual's review.
For patent strategists, the heavy reliance on a single examiner within the Biotechnology & Pharmaceuticals sector is a critical factor. While 2 distinct examiners are involved in the 2 distinct art units, the fact that 4 out of 5 actions belong to ARON, KIMBERLY A means that the company's immediate prosecution success is largely tied to this specific examiner's interpretations.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (40%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARON, KIMBERLY A | 4 | 54.5% | +35.2% |
| ABBOTT, KODYE LEE | 1 | 53.1% | +71.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18639303 | ONCOLYTIC VIRUSES FOR MODIFIED MHC EXPRESSION | ARON, KIMBERLY A | — |
| 18606128 | ONCOLYTIC VIRUSES FOR MODIFIED MHC EXPRESSION | ARON, KIMBERLY A | — |
| 17703094 | Producer Viruses for Generation of Retroviruses In Situ | ABBOTT, KODYE LEE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18892948 | Oncolytic Immunotherapy by Tumor Micro-Environment Remodeling | ARON, KIMBERLY A | — |
| 18892953 | Oncolytic Immunotherapy by Tumor Micro-Environment Remodeling | ARON, KIMBERLY A | — |
| 18639303 | ONCOLYTIC VIRUSES FOR MODIFIED MHC EXPRESSION | ARON, KIMBERLY A | — |
| 18606128 | ONCOLYTIC VIRUSES FOR MODIFIED MHC EXPRESSION | ARON, KIMBERLY A | — |
| 17703094 | Producer Viruses for Generation of Retroviruses In Situ | ABBOTT, KODYE LEE | — |
| Art Unit | Apps |
|---|---|
| 1633 | 2 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18892948 | Oncolytic Immunotherapy by Tumor Micro-Environment Remodeling | ARON, KIMBERLY A | — | §103DP | Non-Final OA | — | Pending | Sep 23, 2024 |
| 18892953 | Oncolytic Immunotherapy by Tumor Micro-Environment Remodeling | ARON, KIMBERLY A | — | §103DP | Non-Final OA | — | Pending | Sep 23, 2024 |
| 18639303 | ONCOLYTIC VIRUSES FOR MODIFIED MHC EXPRESSION | ARON, KIMBERLY A | 1633 | §103§112 | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18606128 | ONCOLYTIC VIRUSES FOR MODIFIED MHC EXPRESSION | ARON, KIMBERLY A | 1633 | §102§103§112 | Non-Final OA | — | Pending | Mar 15, 2024 |
| 17703094 | Producer Viruses for Generation of Retroviruses In Situ | ABBOTT, KODYE LEE | 1634 | §103§112 | Non-Final OA | — | Pending | Mar 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial